Home › Research › Tau biomarkers
Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction
Sperandei S, Paoletti FP, De Pauw M, Gaetani L, Tranfaglia C, Goossens J, Stoops E, Vanmechelen E et al.. medRxiv, 2026-10-14
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Background Nigrostriatal dopaminergic dysfunction, a biological anchor of Parkinson’s disease (PD), is routinely assessed using single-photon emission computed tomography of the dopamine transporter (DaT-SPECT). Dopa decarboxylase (DDC) in cerebrospinal fluid (CSF) is a promising biomarker of dopaminergic dysfunction, but its association with DaT-SPECT has to be demonstrated. Objectives To investigate the association of CSF DDC with DaT-SPECT. Methods We first analysed proteomic and DaT-SPECT data from the Parkinson’s Progression Markers Initiative (PPMI), including PD (n=891), prodromal PD (n=867) and healthy controls (n=161). We then verified this association in a single-center clinical cohort (UNIPG), including PD/Dementia with Lewy Bodies (DLB) (n=78), atypical parkinsonisms (AP, n=11), other neurodegenerative diseases (OND, n=25) and controls (CTRL, n=40). Here, CSF DDC was measured by a novel fully automated quantitative immunoassay. Results In PPMI, among 129 proteins assessed, DDC showed the strongest association with DaT-SPECT (β = −0.132, FDR = 6.92 × 10 −33 ). Across PPMI and UNIPG cohorts, DDC correlated with striatal binding ratio (SBR) (ρ = −0.377, P < 0.001; ρ = −0.466, P < 0.001, respectively) and accurately discriminated positive from negative scans (AUC 0.811, 95% CI 0.762–0.859; AUC 0.870, 95% CI 0.777–0.963, respectively). In PPMI prodromal cases, higher DDC predicted faster motor progression. In UNIPG, DDC distinguished PD/DLB and AP from OND and CTRL groups (AUC 0.830, 95% CI 0.764–0.896), independently of dopaminergic treatment. Conclusion CSF DDC reflects nigrostriatal dopaminergic dysfunction, representing a potential quantitative biochemical alternative to DaT-SPECT that might be readily implemented via automated immunoassays.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sperandei, S., Paoletti, F. P., De Pauw, M., Gaetani, L., Tranfaglia, C., Goossens, J., et al. (2026). Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction. medRxiv. https://doi.org/10.64898/2026.10.13.26364985
Vancouver
Sperandei S, Paoletti FP, De Pauw M, Gaetani L, Tranfaglia C, Goossens J, et al. Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction. medRxiv. 2026. doi:10.64898/2026.10.13.26364985.
BibTeX
@article{sperandei2026-643ae72b,
author = {Sperandei, S. and Paoletti, F. P. and De Pauw, M. and Gaetani, L. and Tranfaglia, C. and Goossens, J. and Stoops, E. and Vanmechelen, E. and others},
title = {{Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.10.13.26364985},
url = {https://doi.org/10.64898/2026.10.13.26364985}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Dopa decarboxylase (DDC) in cerebrospinal fluid (CSF) is a promising biomarker of dopaminergic dysfunction, but its association with DaT-SPECT has to be demonstrated.
- Results In PPMI, among 129 proteins assessed, DDC showed the strongest association with DaT-SPECT (β = −0.132, FDR = 6.92 × 10 −33 ).
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants891
- Effect sizeAUC 0.811; AUC 0.870; AUC 0.830
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 37 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 62 points we could judge it on, which is 37 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 891 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 23 of the 62 points we could judge it on is 37 out of 100. |
| Total | 37 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also in Tau biomarkers
62 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.